Although clinical trials in mesothelioma are still limited, preclinical studies in murine models have demonstrated efficacy of CD40 agonists as monotherapy [150] not just in adjuvant settings post-surgery [151] but also in combination with other immunostimulatory agents, such as TLR ligands and IL-2 [152,153,154,155]. This evidence concerns the gene IL2 and mesothelioma.